flow trial semaglutide kidney outcomes nejm 2024 hazard ratio 0.76 reduced the risk of clinically important and death from cardiovascular (CV) causes in patients with type 2 diabetes (T2D) and CKD ca. #ERA24 🇸🇪 #Nephpearls https://www.nejm .org/doi/full/10.1056/NEJMoa2403347 FLOW- the Visual Abstract —

Conversely, if you experience early-morning nausea from any medications, evening injection avoids compounding that natural pattern

Building on the findings from the SURMOUNT-OSA trial, which demonstrated tirzepatides efficacy in improving OSA in nondiabetic patients, this study investigated whether OSA modifies the mortality benefit associated with GLP-1 use among individuals with diabetes in a large, real-world population

Gastrointestinal side effects from GLP-1 therapy (nausea, constipation) may feel more pronounced if your stomach acid is already reduced

The pharmacokinetic properties including intestinal permeability, first-pass metabolism, microbiota-mediated biotransformation, plasma half-life, and systemic availability is essential for translational relevance

Expect to see the most significant changes after three to four months of consistent use alongside solid lifestyle foundations